Skip to content

Study · Randomized controlled trial · n = 12 · 2020

6 results

Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers.

Pellesi L, Al-Karagholi MA, Chaudhry BA, Lopez CL, Snellman J, Hannibal J, Amin FM, Ashina M

Cephalalgia : an international journal of headache27 Jun 2020Cited by 42 (Europe PMC)

PMID32594760 (opens in a new tab)DOI10.1177/0333102420937655 (opens in a new tab)PepBankPUB-32594760
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialOther

    In healthy volunteers, a 2-hour intravenous VIP infusion made the superficial temporal artery significantly wider than placebo.

    In plain wordsIn healthy volunteers, a 2-hour VIP infusion widened a scalp artery more than placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseSuperficial temporal artery diameter
    Study

    n = 12

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    The superficial temporal artery diameter was significantly larger on the VIP day compared to placebo (p < 0.001)
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.
  2. 02HumanRandomized controlled trialOther

    In healthy volunteers, headache was more frequent after a 2-hour VIP infusion than after placebo.

    In plain wordsIn healthy volunteers, headache happened more often after a 2-hour VIP infusion than after placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseIncidence of headache
    Study

    n = 12

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    The incidence of headache was higher (p = 0.003) on the VIP day compared to the placebo day.
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.
  3. 03HumanRandomized controlled trialOther

    In healthy volunteers, the dilation of the superficial temporal artery after a 2-hour VIP infusion lasted for more than 2 h.

    In plain wordsIn healthy volunteers, the scalp artery stayed wider for more than 2 hours after a 2-hour VIP infusion.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseDuration of superficial temporal artery dilation
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    the dilation lasted for more than 2 h.
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.
  4. 04HumanRandomized controlled trialOther

    In healthy volunteers, headache intensity was higher in the period 120-200 min after a 2-hour VIP infusion than after placebo.

    In plain wordsIn healthy volunteers, headache was stronger after the infusion ended than after placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHeadache intensity in the post-infusion period (120-200 min)
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    The difference in headache intensity scores was more evident in the post-infusion period (120-200 min, p = 0.034)
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.
  5. 05HumanRandomized controlled trialOther

    In healthy volunteers, headache intensity was higher in the 4-12 h post-hospital phase after a 2-hour VIP infusion than after placebo.

    In plain wordsIn healthy volunteers, headache was stronger 4 to 12 hours after a VIP infusion than after placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHeadache intensity in the post-hospital phase (4-12 h)
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    and in the post-hospital phase (4-12 h, p = 0.025)
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.
  6. 06HumanRandomized controlled trialOther

    In healthy volunteers, tear production, a measure of cranial parasympathetic activity, was higher during VIP infusion than during placebo.

    In plain wordsIn healthy volunteers, tear production was higher during a VIP infusion than during placebo.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseCranial parasympathetic activity (tear production)
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    Cranial parasympathetic activity, measured through the production of tears, was higher during VIP compared to placebo (p = 0.033).
    1 context sentence
    Summary · context
    In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03989817

The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers

Danish Headache Centern = 1214 Jun 2019 to 30 Jun 2020

Headache Disorders

Trial pageClinicalTrials.govUpdated 20 Aug 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.